Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

ConclusionPatients with moderate hepatic impairment showed mildly increased AUC0 –inf for rucaparib compared to patients with normal hepatic function. Although more patients with moderate hepatic impairment experienced TEAEs, only 2 TEAEs were considered treatment related. These results suggest no starting dose adjustment is necessary for patients with moderate hepatic impairment; however, close safety monitoring is warranted.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research